CAR-T Therapy for Acute Lymphoblastic Leukemia (ALL) at Sheba Medical Center

• العلاج بالخلايا التائية ذات مستقبل المستضد الخيمري
• فحص دم
• فحص كيمياء الدم
• خزعة
• التصوير المقطعي المحوسب
• استشارة طبيب
• استشارة طبيب أورام
• استشارة طبيب أمراض دم
• طبيب حساسية ومناعة
• استشارة طبيب أمراض دم أطفال
• تعداد الدم الكامل مع كشف أوسام الأورام السرطانية بالإضافة إلى تحليل البروتينات
• تصوير الأوعية المقطعي
• تخطيط كهربية القلب
• فحص متابعة
• الرعاية ما بعد الجراحة
• فحوصات ما قبل العملية الجراحية
• تصوير مقطعي بالإصدار البوزيتروني
• استشارة طبيب سرطان الدم
• خدمات التمريض على مدار الساعة
• ثلاث وجبات يومية من إعداد أخصائي التغذية

• 21 ايام في المستشفى

• نقل المطار والعيادة والمطار

CAR-T Therapy for Acute Lymphoblastic Leukemia (ALL) at Sheba Medical Center

For patients diagnosed with Acute Lymphoblastic Leukemia (ALL), especially those with relapsed or treatment-resistant disease, access to advanced therapy can be life-changing.
Sheba Medical Center, one of the world’s leading hospitals, offers state-of-the-art CAR-T cell therapy, providing new hope where conventional treatments may no longer be effective.
Sheba is recognized as a global leader in CAR-T therapy for ALL, particularly in pediatric and young adult patients, combining cutting-edge science with extensive clinical experience.

A Faster Path to Life-Saving Treatment

At Sheba, the entire CAR-T process is performed on-site, ensuring speed, precision, and optimal cell quality, critical in fast-progressing diseases like ALL.

• Apheresis – collection of the patient’s T-cells
• Cell Engineering – genetic modification at Sheba’s Advanced Biotherapy Center
• Infusion – reinfusion of modified cells designed to target and eliminate leukemia cells

By keeping the entire process in-house, treatment can begin in approximately 10 days, significantly faster than many international centers.
CAR-T therapy acts as a “living drug,” continuing to work in the body and offering the potential for deep and lasting remission.
All patients are treated under the leadership of Prof. Arnon Nagler, a globally recognized expert in hemato-oncology.

Outstanding Outcomes That Offer Real Hope

Sheba is a world leader in pediatric CAR-T for ALL, with exceptional clinical results:

• Up to ~90% remission in pediatric patients
• ~80% in young adults (up to 23 years)
• ~70% in adult patients

These outcomes provide a powerful treatment option and a second chance for patients with limited alternatives.

Why Patients Choose Sheba

• Rapid access to CAR-T therapy – treatment initiation in ~10 days
• Extensive experience – leading CAR-T program in the region
• Dedicated CAR-T units – specialized care with 24/7 monitoring
• Multidisciplinary expertise – hematology, oncology, and immunotherapy teams working together
• Full international support – medical review, travel coordination, and patient assistance

Comprehensive, Personalized Care

Each patient undergoes a full diagnostic evaluation, including advanced imaging, bone marrow biopsy, genetic and molecular testing, and complete medical assessment, ensuring a precise, individualized treatment plan.
Services are available in English, Russian, and Arabic, providing a seamless experience for international patients and their families.

A Global Leader in Advanced Leukemia Care

By combining innovative CAR-T technology, in-house cell production, and world-class expertise, Sheba delivers one of the most advanced and accessible CAR-T programs for ALL worldwide, offering patients not just treatment, but a real opportunity for remission and renewed life.

• منسق طبي خاص
• ترتيبات السفر الطبي - حجز تذاكر السفر الجوي وغرف الفنادق بأسعار خاصة للشركاء
• دعوة المريض أثناء السفر الطبي